The agreement covers the countries of the European Union, the European Economic Area, the United Kingdom, Ukraine, Russia and the CIS Bentracimab is a human monoclonal antibody fragment to counteract the antiplatelet effects of ticagrelor After the recent acquisition of Lumeblue(R), Alfasigma's pipeline is enriched with a biotechnological drug Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), for the commercialization of bentracimab